Enrollment completed in registrational Phase 3 EXPLORER-CN trial of mavacamten, with data expected mid-2023 Mavacamten patient education and physician awareness activities underway in China with inclusion in HCM treatment guidelines, disease awareness campaign launch, and key commercial leadership hired Pivotal […]
Other News
PLx Pharma Inc. Reports Third Quarter 2022 Results and Provides Business Update
– Significant Reduction in Operating Expenses – Strategic Alternatives Process Ongoing Total Net Sales of $0.4 Million, Including $0.3 Million of Unfavorable Adjustments for Additional Trade Allowances and Incremental Sales Returns Reserves in Q3 2022 Total Operating Expenses Significantly Lower by […]
89bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-Completed enrollment in ENLIVEN Phase 2b NASH trial with topline data expected in the first quarter of 2023- -Presented additional post-hoc exploratory analyses from the Phase 1b/2a NASH study of pegozafermin at AASLD The Liver Meeting® 2022- -Reported additional positive data […]
Coronary Stent Co-Inventor and Gene Therapy Pioneer, Dr. Richard Schatz, Joins GATC Health as Chairman of its Medical Advisory Board
IRVINE, Calif., Nov. 10, 2022 /PRNewswire/ — GATC Health (“GATC” or “the Company”), a science and technology company revolutionizing drug discovery and disease prediction using artificial intelligence (AI), today announced that Dr. Richard Schatz has joined its Medical Advisory Board as Chairman. Dr. Schatz, a recognized […]
BD Reports Fourth Quarter and Full Year Fiscal 2022 Financial Results
Execution of BD 2025 Strategy Driving Consistent Durable Growth Q4 revenue from continuing operations of $4.8 billion decreased 1.8% as reported and increased 2.3% on a currency-neutral basis Q4 revenue performance driven by base revenue growth of 4.2% as reported, 8.6% currency-neutral […]
Stereotaxis Reports 2022 Third Quarter Financial Results
ST. LOUIS, Nov. 10, 2022 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2022. “Stereotaxis continues to demonstrate robust commercial […]
CorMedix Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update
Conference Call Scheduled for Today at 8:30 a.m. Eastern Time BERKELEY HEIGHTS, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening […]
Humacyte Third Quarter 2022 Financial Results and Business Update
— Progress Continues in Clinical Development of Human Acellular Vessel™ (HAV™) for Vascular Trauma; BLA Filing Anticipated mid 2023 – — Experience with HAV in Ukrainian War Vascular Trauma Mirrors Clinical Experiences in Civilians in the U.S., High Patency and Low Rates […]
scPharmaceuticals Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update
Announced FDA marketing approval of FUROSCIX® (furosemide injection), the first and only self-administered, subcutaneous loop diuretic for the at-home treatment of congestion in chronic heart failure Entered into a secured debt financing agreement for up to $100 million with funds managed […]
BioCardia Reports Third Quarter 2022 Business Highlights and Financial Results
SUNNYVALE, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the third quarter of 2022 and filed its quarterly report […]